July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Systemic PDE 5/6 treatment of macular disease and dystrophy – long term vision and OCT results
Author Affiliations & Notes
  • D Jackson Coleman
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Winston Lee
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Stanley Chang
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Suzanne Daly
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Harriet O Lloyd
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Stephen H Tsang
    Ophthalmology, Columbia University Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   D Jackson Coleman, None; Winston Lee, None; Stanley Chang, None; Suzanne Daly, None; Harriet Lloyd, None; Stephen Tsang, None
  • Footnotes
    Support  Triad Foundation Grant
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 69. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D Jackson Coleman, Winston Lee, Stanley Chang, Suzanne Daly, Harriet O Lloyd, Stephen H Tsang; Systemic PDE 5/6 treatment of macular disease and dystrophy – long term vision and OCT results. Invest. Ophthalmol. Vis. Sci. 2018;59(9):69. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate inhibition of PDE 5/6 with sildenafil to reduce choroidal ischemia and treat age-related macular degeneration, retinitis pigmentosa and central serous retinopathy.

Methods : In a series of 10 patients in an IRB-approved study at Columbia University Medical Center, sildenafil was prescribed to treat participants with macular disease. Spectral Domain-Optical Coherence Tomography (OCT), color fundus photography, Enhanced Depth Imaging-OCT and Best Corrected Visual Acuity (BCVA) data were acquired.

Results : No loss of vision was noted after 30 months follow up for most patients. No change to calcified drusen was noted. Vitelliform-type soft drusen were not substantially changed. A patient with Best vitelliform macular dystrophy had a significant improvement in vision and photoreceptor and ellipsoid layers, and a patient with central serous retinopathy showed early and significant improvement.

Conclusions : Our research supports the use of sildenafil as a safe treatment for age-related and vitelliform macular degenerations. Thickened Bruch’s membrane reduces the beneficial effect of perfusion-increase, but all eyes appear to benefit from PDE6 inhibition. Notably, the maintenance or improvement in the photoreceptor layer may be the most significant result of sildenafil and is consistent with PDE6 inhibition. Central serous retinopathy shows early and complete resorption of serous fluid.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×